Ha (bows) when you put it so politely how can I not acquiesce to your request. I agree that with the recent transaction it is now a past issue (which incidentally is why I believe the company agreed to it, just to say “look let’s just move on”).
There are plenty of things that I can think of that Kza would have that nox would find useful in taking the drug forward, such as results from a myriad of preclinical testing and clinical trial data performed by novogen through the years.
Ann: Appendix 4D and Half Year Accounts, page-24
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |